AU2006265632B2 - HCV inhibitors - Google Patents

HCV inhibitors Download PDF

Info

Publication number
AU2006265632B2
AU2006265632B2 AU2006265632A AU2006265632A AU2006265632B2 AU 2006265632 B2 AU2006265632 B2 AU 2006265632B2 AU 2006265632 A AU2006265632 A AU 2006265632A AU 2006265632 A AU2006265632 A AU 2006265632A AU 2006265632 B2 AU2006265632 B2 AU 2006265632B2
Authority
AU
Australia
Prior art keywords
alkyl
amino
compound
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006265632A
Other languages
English (en)
Other versions
AU2006265632A1 (en
Inventor
Michael Graupe
John O. Link
Chandrasekar Venkataramani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virobay Inc
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of AU2006265632A1 publication Critical patent/AU2006265632A1/en
Application granted granted Critical
Publication of AU2006265632B2 publication Critical patent/AU2006265632B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006265632A 2005-06-30 2006-06-29 HCV inhibitors Ceased AU2006265632B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69576705P 2005-06-30 2005-06-30
US60/695,767 2005-06-30
US11/478,337 US7608592B2 (en) 2005-06-30 2006-06-28 HCV inhibitors
US11/478,337 2006-06-28
PCT/US2006/025996 WO2007005838A2 (en) 2005-06-30 2006-06-29 Hcv inhibitors

Publications (2)

Publication Number Publication Date
AU2006265632A1 AU2006265632A1 (en) 2007-01-11
AU2006265632B2 true AU2006265632B2 (en) 2012-03-29

Family

ID=37605137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006265632A Ceased AU2006265632B2 (en) 2005-06-30 2006-06-29 HCV inhibitors

Country Status (14)

Country Link
US (2) US7608592B2 (https=)
EP (2) EP1906945B1 (https=)
JP (2) JP5368089B2 (https=)
KR (1) KR101369872B1 (https=)
AU (1) AU2006265632B2 (https=)
BR (1) BRPI0612104A8 (https=)
CA (1) CA2613112C (https=)
EA (1) EA015415B1 (https=)
ES (1) ES2552712T3 (https=)
IL (1) IL188207A (https=)
MX (1) MX2007016324A (https=)
NO (1) NO20080540L (https=)
NZ (1) NZ564257A (https=)
WO (1) WO2007005838A2 (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
AU2006276246B2 (en) * 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
ES2356776T3 (es) * 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
AU2007249668B2 (en) 2006-04-11 2011-04-07 Novartis Ag HCV/HIV inhibitors and their uses
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
PT2041156E (pt) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
JP2010519339A (ja) 2007-02-26 2010-06-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖ複製阻害剤として有用な三級アミン置換ペプチド
SG174809A1 (en) * 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
JP2010526834A (ja) 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
RU2515318C2 (ru) 2007-12-21 2014-05-10 Авила Терапьютикс, Инк. Ингибиторы протеазы вируса гепатита с и их применение
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TWI487522B (zh) 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Ｈｃｖ蛋白酶抑制劑及其用途（一）
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8211897B2 (en) * 2008-02-07 2012-07-03 Virobay, Inc. Inhibitors of cathepsin B
US8431733B2 (en) * 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2364309B1 (en) 2008-12-10 2014-10-01 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN102741270B (zh) * 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
RU2576316C2 (ru) 2010-11-03 2016-02-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидная композиция, способ контроля вредителей, способ контроля эндопаразитов, эктопаразитов или обоих и способ усиления жизнестойкости растений
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6027128B2 (ja) 2011-10-26 2016-11-16 ダウ アグロサイエンシィズ エルエルシー 有害生物防除組成物およびそれに関連した方法
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
BR122014028247A2 (pt) 2012-04-27 2019-05-07 Dow Agrosciences Llc composições pesticidas, processo para controlar praga, uso de uma molécula, processo para aumentar a saúde, rendimento, vigor, qualidade ou tolerância de uma planta e processos para produção de compostos
CA2905433A1 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
EP3057429A4 (en) 2013-10-17 2017-08-09 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2926095A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
JP2016539092A (ja) 2013-10-17 2016-12-15 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
AR098100A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y los métodos relacionados
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
MX2016005305A (es) 2013-10-22 2017-03-01 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
JP2016534073A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
US9282740B2 (en) 2013-10-22 2016-03-15 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AU2014340424B2 (en) 2013-10-22 2017-06-29 Dow Agrosciences Llc Pesticidal compositions and related methods
US9295260B2 (en) 2013-10-22 2016-03-29 Dow Agrosciences Llc Pesticidal compositions and related methods
RU2656894C2 (ru) 2013-10-22 2018-06-07 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и соответствующие способы
US9788545B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098099A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y los métodos relacionados
JP2016535026A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
KR20160074628A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
AR098101A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
EP3060044A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
NZ719952A (en) 2013-10-22 2017-05-26 Dow Agrosciences Llc Pesticidal compositions and related methods
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3149024B9 (en) 2014-05-28 2021-10-27 Agensys, Inc. Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
JP2017523168A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
AR098113A1 (es) 2014-09-12 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
JP2020503336A (ja) 2016-12-29 2020-01-30 ダウ アグロサイエンシィズ エルエルシー 殺有害生物化合物の調製方法
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009543A2 (en) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
EP1136498A1 (en) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
WO2002018369A2 (en) * 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
US20030216325A1 (en) * 2000-07-21 2003-11-20 Saksena Anil K Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2005035525A2 (en) * 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005113581A1 (en) * 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) * 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6404397B1 (en) 1998-08-10 2002-06-11 Raytheon Company Compact all-weather electromagnetic imaging system
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6774212B2 (en) 1999-12-03 2004-08-10 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
CN1788006A (zh) 2003-04-18 2006-06-14 安南塔制药公司 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
DE502004010400D1 (de) * 2003-08-22 2009-12-31 Glatz Ag An einem träger verschwenkbar angeordneter ausleger für einen freiarmschirm
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP1730165A1 (en) 2004-02-27 2006-12-13 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
EP1915382A2 (en) * 2005-08-01 2008-04-30 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
US20090304631A1 (en) * 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136498A1 (en) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
WO2000009543A2 (en) * 1998-08-10 2000-02-24 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US20030216325A1 (en) * 2000-07-21 2003-11-20 Saksena Anil K Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002018369A2 (en) * 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
WO2005035525A2 (en) * 2003-09-05 2005-04-21 Vertex Pharmaceuticals Incorporated 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005113581A1 (en) * 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Goudreau et al. (2004) Journal of Organic Chemistry 69 (19): 6185-6201 *
Malancona et al. (2004) Bioorganic & Medicinal Chemistry Letters 14: 4575-4579 *

Also Published As

Publication number Publication date
EP1906945A4 (en) 2009-07-15
EA200800178A1 (ru) 2008-10-30
EA015415B1 (ru) 2011-08-30
WO2007005838A2 (en) 2007-01-11
MX2007016324A (es) 2008-04-07
KR101369872B1 (ko) 2014-03-06
US20100266537A1 (en) 2010-10-21
KR20080027803A (ko) 2008-03-28
CA2613112C (en) 2017-06-13
US7608592B2 (en) 2009-10-27
US20070054864A1 (en) 2007-03-08
JP5368089B2 (ja) 2013-12-18
AU2006265632A1 (en) 2007-01-11
JP2012176973A (ja) 2012-09-13
BRPI0612104A8 (pt) 2017-12-26
NO20080540L (no) 2008-03-28
CA2613112A1 (en) 2007-01-11
BRPI0612104A2 (pt) 2012-09-04
WO2007005838A3 (en) 2008-01-17
EP2431379A3 (en) 2013-05-15
NZ564257A (en) 2012-01-12
IL188207A (en) 2015-10-29
ES2552712T3 (es) 2015-12-01
US8518874B2 (en) 2013-08-27
EP2431379A2 (en) 2012-03-21
EP1906945A2 (en) 2008-04-09
EP1906945B1 (en) 2015-08-05
JP2009500353A (ja) 2009-01-08
IL188207A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
AU2006265632B2 (en) HCV inhibitors
CN101443350B (zh) 作为抗病剂的大环化合物
JP5254964B2 (ja) 抗ウイルス剤としての大環状化合物
US7585845B2 (en) Hepatitis C inhibitor compounds
US20080161254A1 (en) Hcv inhibitors
JP5608563B2 (ja) 治療用化合物
US8273709B2 (en) Triazole-containing macrocyclic HCV serine protease inhibitors
US8940688B2 (en) Fluorinated tripeptide HCV serine protease inhibitors
WO2009073713A1 (en) Oximyl macrocyclic derivatives
CA2713108A1 (en) Inhibitors of cathepsin b
KR20100017547A (ko) 신규 시클릭 펩티드 화합물
CN101980719A (zh) 含杂芳基的三肽hcv丝氨酸蛋白酶抑制剂
CN101242816A (zh) Hcv抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired